CY1120816T1 - Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινων - Google Patents
Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινωνInfo
- Publication number
- CY1120816T1 CY1120816T1 CY181101112T CY181101112T CY1120816T1 CY 1120816 T1 CY1120816 T1 CY 1120816T1 CY 181101112 T CY181101112 T CY 181101112T CY 181101112 T CY181101112 T CY 181101112T CY 1120816 T1 CY1120816 T1 CY 1120816T1
- Authority
- CY
- Cyprus
- Prior art keywords
- allantotoxin
- skindeum
- allantotoxins
- release
- local application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Μια σύνθεση για τοπική εφαρμογή αλλαντοτοξίνης (συμπεριλαμβανομένων των παραγώγων αλλαντοτοξίνης) που περιλαμβάνει μια αλλαντοτοξίνη και έναν φορέα ο οποίος περιλαμβάνει πολυμερική ραχοκοκαλιά που περιλαμβάνει μακράς αλύσου πολυπεπτιδικό ή μη πεπτιδυλικό πολυμερές που έχει συνδεδεμένες θετικά φορτισμένες ομάδες διακλάδωσης ή «αποτελεσματικότητας». Η εφεύρεση αφορά επίσης σε μεθόδους μείωσης της μυϊκής παράλυσης και άλλων παθήσεων που μπορούν να αντιμετωπιστούν θεραπευτικά με μια αλλαντοτοξίνη, ιδίως παράλυση υποδορίων μυών, με τοπική εφαρμογή μιας αποτελεσματικής ποσότητας της αλλαντοτοξίνης και του φορέα, σε συνδυασμό, στο δέρμα ή στο επιθήλιο του υποκειμένου. Περιγράφονται επίσης κιτ για χορήγηση.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55001504P | 2004-03-03 | 2004-03-03 | |
EP13173674.6A EP2656859B1 (en) | 2004-03-03 | 2005-03-03 | Topical application and transdermal delivery of botulinum toxins |
EP05731866.9A EP1729821B1 (en) | 2004-03-03 | 2005-03-03 | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
PCT/US2005/007524 WO2005084410A2 (en) | 2004-03-03 | 2005-03-03 | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120816T1 true CY1120816T1 (el) | 2019-12-11 |
Family
ID=34919562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181101112T CY1120816T1 (el) | 2004-03-03 | 2018-10-30 | Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινων |
Country Status (25)
Country | Link |
---|---|
US (2) | US8398997B2 (el) |
EP (3) | EP1729821B1 (el) |
JP (1) | JP5095388B2 (el) |
KR (3) | KR101343411B1 (el) |
CN (2) | CN102357062B (el) |
AU (1) | AU2005218665A1 (el) |
BR (1) | BRPI0508410B8 (el) |
CA (1) | CA2558408C (el) |
CR (1) | CR8602A (el) |
CY (1) | CY1120816T1 (el) |
DK (3) | DK2656859T3 (el) |
ES (3) | ES2691498T3 (el) |
HK (4) | HK1105774A1 (el) |
HU (1) | HUE025656T2 (el) |
IL (4) | IL177816A (el) |
LT (1) | LT2985039T (el) |
MX (2) | MX345724B (el) |
NO (1) | NO20064490L (el) |
NZ (1) | NZ592041A (el) |
PL (1) | PL2985039T3 (el) |
PT (3) | PT1729821E (el) |
SG (3) | SG10201400339VA (el) |
SI (3) | SI1729821T1 (el) |
TR (1) | TR201815364T4 (el) |
WO (1) | WO2005084410A2 (el) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
AU8466501A (en) * | 2000-07-21 | 2002-02-05 | Essentia Biosystems Inc | Multi-component biological transport systems |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
KR101108439B1 (ko) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | 화장료 및 약제용 거품제 |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
SG150570A1 (en) | 2004-03-03 | 2009-03-30 | Revance Therapeutics Inc | Compositions and methods for topical diagnostic and therapeutic transport |
ES2691498T3 (es) | 2004-03-03 | 2018-11-27 | Revance Therapeutics, Inc. | Aplicación tópica y liberación transdérmica de toxinas botulínicas |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
US20080220021A1 (en) * | 2005-02-14 | 2008-09-11 | Pankaj Modi | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis |
AU2013201374B2 (en) * | 2005-03-03 | 2015-05-21 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CN102499981B (zh) | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
AU2006298442A1 (en) | 2005-05-09 | 2007-04-12 | Foamix Ltd. | Saccharide foamable compositions |
BRPI0611134A2 (pt) | 2005-06-03 | 2010-08-17 | Acrux Dds Pty Ltd | método e composição para liberação transdérmica de fármaco |
CA2618655C (en) | 2005-07-18 | 2015-12-22 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
WO2007119099A2 (en) * | 2005-09-12 | 2007-10-25 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
BRPI0618753A2 (pt) * | 2005-11-17 | 2011-09-13 | Revance Therapeutics Inc | composição para liberação transdérmica de toxina botulìnica e método de administração |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
DK3144013T3 (en) | 2005-12-01 | 2019-03-04 | Univ Massachusetts Lowell | Botulinum nanoemulsions |
EP1984399A4 (en) * | 2006-02-10 | 2010-03-03 | Univ California | TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
BRPI0719732A2 (pt) | 2006-12-01 | 2017-05-16 | Anterios Inc | nanopartículas de peptídeo e usos para as mesmas |
BRPI0719756A2 (pt) | 2006-12-01 | 2014-01-21 | Anterios Inc | Nanopartículas de entidades anfifílicas |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
KR20090096735A (ko) * | 2006-12-29 | 2009-09-14 | 레반스 테라퓨틱스, 아이엔씨. | Hiv-tat로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법 |
CN101583274A (zh) * | 2006-12-29 | 2009-11-18 | 雷文斯治疗公司 | 使用反向序列hiv-tat多肽的运输分子 |
EP2152293B1 (en) * | 2007-05-11 | 2016-10-19 | The Board of Regents of the University of Nebraska | Compositions for protein delivery and methods of use thereof |
KR20100050443A (ko) | 2007-05-31 | 2010-05-13 | 안테리오스, 인코퍼레이티드 | 핵산 나노입자 및 이의 용도 |
CA2694046C (en) * | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009056991A2 (en) * | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
HUE046037T2 (hu) | 2008-03-14 | 2020-01-28 | Allergan Inc | Immun-alapú, A szerotípusú botulinum toxin aktivitás vizsgálati eljárások |
SG172811A1 (en) * | 2008-12-31 | 2011-08-29 | Revance Therapeutics Inc | Compositions and methods for treating hyperpigmentation |
KR102005930B1 (ko) * | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
EP2413947B1 (en) | 2009-04-01 | 2020-04-29 | Revance Therapeutics, Inc. | Methods and compositions for treating skin conditions associated with vascular hyper-reactivity |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CN102869373B (zh) | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011041483A2 (en) * | 2009-09-30 | 2011-04-07 | Toxcure, Inc. | Use of botulinum neurotoxin to treat substance addictions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
EP2482788B1 (en) | 2009-10-02 | 2022-12-14 | Journey Medical Corporation | Topical tetracycline compositions |
WO2011049954A2 (en) * | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
CN102639183B (zh) * | 2009-10-30 | 2016-05-04 | 雷文斯治疗公司 | 用于局部施用治疗或美容组合物的装置和方法 |
IN2012DN06631A (el) * | 2010-02-16 | 2015-10-23 | Pfizer | |
WO2011109151A1 (en) * | 2010-03-03 | 2011-09-09 | 3M Innovative Properties Company | Ligand guanidinyl functionalized polymers |
US8978936B2 (en) | 2010-07-12 | 2015-03-17 | Foamix Pharmaceuticals Ltd. | Apparatus and method for releasing a unit dose of content from a container |
JP6444032B2 (ja) | 2011-01-07 | 2018-12-26 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 治療用又は美容用毒素組成物の局所塗布、除去及び不活化のための方法及びキット |
TR201905477T4 (tr) * | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-parçacık bileşimler. |
US8791072B2 (en) * | 2011-02-28 | 2014-07-29 | Neuro-Ophthalmix, Llc | Modulating neuromuscular junction density changes in botulinum-toxin treated tissue |
US9498533B2 (en) | 2011-04-04 | 2016-11-22 | Board Of Regents Of The University Of Nebraska | Drug delivery compositions and methods |
RU2014103543A (ru) * | 2011-07-20 | 2015-08-27 | Аллерган, Инк. | Ботулотоксины для применения в способе лечения жировых отложений |
KR20140139010A (ko) * | 2012-03-22 | 2014-12-04 | 레반스 테라퓨틱스, 아이엔씨. | 국소 화학탈신경제를 이용한 주름 치료 방법 |
EP2885313A4 (en) | 2012-08-20 | 2016-03-09 | Univ California | POLYNUCLEOTIDES WITH BIOREVERSIBLE GROUPS |
MX370929B (es) * | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
US20160166487A1 (en) | 2013-07-30 | 2016-06-16 | Glaxosmithkline Intellectual Property Development Limited | Topical compositions for treatment of excessive sweating and methods of use thereof |
CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
SG11201704699YA (en) | 2014-12-08 | 2017-07-28 | JJSK R&D Pte Ltd | Carrier molecule compositions and related methods |
FR3030524B1 (fr) * | 2014-12-17 | 2017-01-20 | Hydro-Fill | Utilisation de pll pour ameliorer la stabilite de molecules en solution |
KR101876177B1 (ko) * | 2016-02-17 | 2018-07-09 | 가톨릭관동대학교산학협력단 | 경피투과 보툴리눔 독소 패치 |
KR101997474B1 (ko) | 2016-06-13 | 2019-07-09 | 기초과학연구원 | 쿠커비투[n]릴을 이용하여 신경전달물질을 제어하는 방법 및 이의 용도 |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
HRP20191966T4 (hr) | 2016-09-13 | 2022-09-16 | Allergan, Inc. | Stabilizirani neproteinski klostridijalni pripravci toksina |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
MX2019013716A (es) * | 2017-05-18 | 2020-10-12 | Revance Therapeutics Inc | Métodos de tratamiento para la distonía cervical. |
US11773145B2 (en) | 2017-07-21 | 2023-10-03 | Shanghaitech University | Topical compositions and uses |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
US10918586B2 (en) * | 2017-12-07 | 2021-02-16 | Ps Therapy Ltd. | Topical compositions and methods of use thereof |
CN112351991A (zh) | 2017-12-20 | 2021-02-09 | 阿勒根公司 | 肉毒杆菌毒素细胞结合结构域多肽及其用于治疗纤维化相关障碍的方法 |
KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
US11191819B2 (en) | 2018-08-28 | 2021-12-07 | Ira Sanders | Skin therapeutics |
US20220079873A1 (en) * | 2020-09-11 | 2022-03-17 | Ps Therapy Ltd. | Topical compositions and methods of use |
US20240099962A1 (en) * | 2020-12-09 | 2024-03-28 | Dermata Therapeutics, Inc. | Compositions for the treatment of skin conditions |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
JPS63287730A (ja) * | 1987-05-20 | 1988-11-24 | Nippon Shokubai Kagaku Kogyo Co Ltd | 経皮吸収促進剤およびこれを含有してなる皮膚外用剤 |
US5252713A (en) | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5420105A (en) | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US6986893B2 (en) | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
EP1598077B1 (en) | 1993-12-28 | 2009-11-04 | Allergan, Inc. | Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9600272D0 (en) | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
CA2291074C (en) | 1997-05-21 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
US5985434A (en) | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
AU1818299A (en) | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6261679B1 (en) | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
JP2002520435A (ja) | 1998-07-13 | 2002-07-09 | エクスプレション・ジェネティックス・インコーポレーテッド | 可溶性、生物分解性な遺伝子輸送キャリアーとしてのポリ−l−リジンのポリエステル類似体 |
US6280937B1 (en) | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
ATE314859T1 (de) | 1998-10-27 | 2006-02-15 | Mayo Foundation | Botulinumtoxine zur verstärkung der wundheilung |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US7056656B1 (en) | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US7008924B1 (en) | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6610820B1 (en) | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US20030219462A1 (en) | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
AU8466501A (en) * | 2000-07-21 | 2002-02-05 | Essentia Biosystems Inc | Multi-component biological transport systems |
US20030215412A1 (en) | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US7255865B2 (en) | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
CA2451923C (en) * | 2001-07-27 | 2009-10-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
WO2003015698A2 (en) * | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
JP2005508990A (ja) | 2001-11-07 | 2005-04-07 | ファルマシア・コーポレーション | 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法 |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
WO2003049772A2 (en) | 2001-12-11 | 2003-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
EP1572941A4 (en) | 2002-02-26 | 2009-03-18 | Maxygen Inc | NEW FLAVIVIRUS ANTIGENES |
ATE494010T1 (de) * | 2002-02-27 | 2011-01-15 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
NZ537120A (en) | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
US20040247623A1 (en) | 2003-03-24 | 2004-12-09 | Roger Cady | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US20040192754A1 (en) | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
WO2005030119A2 (en) | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
ES2691498T3 (es) | 2004-03-03 | 2018-11-27 | Revance Therapeutics, Inc. | Aplicación tópica y liberación transdérmica de toxinas botulínicas |
SG150570A1 (en) | 2004-03-03 | 2009-03-30 | Revance Therapeutics Inc | Compositions and methods for topical diagnostic and therapeutic transport |
US7691381B2 (en) | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
CA2578250C (en) | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
CN102499981B (zh) | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
-
2005
- 2005-03-03 ES ES15185714.1T patent/ES2691498T3/es active Active
- 2005-03-03 PT PT57318669T patent/PT1729821E/pt unknown
- 2005-03-03 CN CN201110302681.3A patent/CN102357062B/zh active Active
- 2005-03-03 SI SI200531786T patent/SI1729821T1/sl unknown
- 2005-03-03 MX MX2011011878A patent/MX345724B/es unknown
- 2005-03-03 EP EP05731866.9A patent/EP1729821B1/en active Active
- 2005-03-03 LT LTEP15185714.1T patent/LT2985039T/lt unknown
- 2005-03-03 CN CN2005800129223A patent/CN1946431B/zh active Active
- 2005-03-03 SG SG10201400339VA patent/SG10201400339VA/en unknown
- 2005-03-03 KR KR1020067020210A patent/KR101343411B1/ko active IP Right Grant
- 2005-03-03 AU AU2005218665A patent/AU2005218665A1/en not_active Abandoned
- 2005-03-03 PT PT15185714T patent/PT2985039T/pt unknown
- 2005-03-03 ES ES05731866T patent/ES2431610T3/es active Active
- 2005-03-03 SG SG10201803560WA patent/SG10201803560WA/en unknown
- 2005-03-03 SI SI200532033T patent/SI2656859T1/sl unknown
- 2005-03-03 PT PT131736746T patent/PT2656859E/pt unknown
- 2005-03-03 HU HUE13173674A patent/HUE025656T2/en unknown
- 2005-03-03 KR KR1020127012049A patent/KR101322433B1/ko active IP Right Grant
- 2005-03-03 PL PL15185714T patent/PL2985039T3/pl unknown
- 2005-03-03 KR KR1020137011291A patent/KR101330775B1/ko active IP Right Grant
- 2005-03-03 BR BRPI0508410A patent/BRPI0508410B8/pt not_active IP Right Cessation
- 2005-03-03 DK DK13173674.6T patent/DK2656859T3/en active
- 2005-03-03 SG SG200901491-1A patent/SG150568A1/en unknown
- 2005-03-03 WO PCT/US2005/007524 patent/WO2005084410A2/en active Application Filing
- 2005-03-03 EP EP15185714.1A patent/EP2985039B1/en active Active
- 2005-03-03 DK DK15185714.1T patent/DK2985039T3/en active
- 2005-03-03 US US10/591,732 patent/US8398997B2/en active Active
- 2005-03-03 MX MXPA06009898A patent/MXPA06009898A/es active IP Right Grant
- 2005-03-03 CA CA2558408A patent/CA2558408C/en active Active
- 2005-03-03 SI SI200532235T patent/SI2985039T1/sl unknown
- 2005-03-03 ES ES13173674.6T patent/ES2554821T3/es active Active
- 2005-03-03 JP JP2007502108A patent/JP5095388B2/ja not_active Expired - Fee Related
- 2005-03-03 NZ NZ592041A patent/NZ592041A/xx unknown
- 2005-03-03 EP EP13173674.6A patent/EP2656859B1/en active Active
- 2005-03-03 DK DK05731866.9T patent/DK1729821T3/da active
- 2005-03-03 US US11/072,026 patent/US8404249B2/en active Active
- 2005-03-03 TR TR2018/15364T patent/TR201815364T4/tr unknown
-
2006
- 2006-08-31 IL IL177816A patent/IL177816A/en active IP Right Grant
- 2006-09-07 CR CR8602A patent/CR8602A/es not_active Application Discontinuation
- 2006-10-03 NO NO20064490A patent/NO20064490L/no not_active Application Discontinuation
-
2007
- 2007-10-11 HK HK07110993.9A patent/HK1105774A1/xx unknown
-
2012
- 2012-04-12 HK HK12103636.0A patent/HK1162952A1/zh unknown
-
2013
- 2013-11-26 HK HK13113158.6A patent/HK1185563A1/xx unknown
-
2015
- 2015-02-24 IL IL237388A patent/IL237388A/en active IP Right Grant
- 2015-02-24 IL IL237386A patent/IL237386A/en active IP Right Grant
-
2016
- 2016-08-17 HK HK16109840.5A patent/HK1221650A1/zh unknown
-
2017
- 2017-06-19 IL IL25300717A patent/IL253007B/en active IP Right Grant
-
2018
- 2018-10-30 CY CY181101112T patent/CY1120816T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120816T1 (el) | Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινων | |
CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
AR051676A1 (es) | Composiciones oftalmicas que comprenden polimeros sustituidos con polieter | |
BR0306993A (pt) | Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c | |
HK1119934A1 (en) | Compositions and methods for topical application and transdermal delivery of botulinum toxins | |
DE69513395T2 (de) | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden | |
BRPI0417213A (pt) | tratamento de gliomas malìgnos com inibidores de tgf-beta | |
PT1061900E (pt) | Composicoes e metodos para libertacao de uma droga | |
BRPI0407397A (pt) | Evento de algodão mon 88913 e composições e métodos para sua detecção | |
BRPI0513370A (pt) | uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv) | |
BRPI0413086A (pt) | matriz complexa, utilização da mesma, e processo de preparação de uma matriz biocompatìvel pouco biodegradável | |
DE60335608D1 (de) | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung | |
BR0115834A (pt) | Polìmeros em forma de pente modificados cationicamente, na base de ácido acriloildimetiltaurìnico | |
BR0206734A (pt) | Polìmeros de ioneno e seu uso como agentes antimicrobianos | |
ATE422875T1 (de) | Verfahren zur behandlung von haar mit einem mizellaren vernetzten copolymer | |
ATE471954T1 (de) | Teilneutralisiertes anionisches (meth)acrylat- copolymer | |
CY1115550T1 (el) | Λαμινινη (lαμινiν)-1 για χρηση στην αυξηση της αναγεννησης μυων ή για βελτιωση της ιασης τραυματος που χορηγειται συστημικα | |
ATE456393T1 (de) | Haarfärbemittel enthaltend organosilikon- copolymere mit aminogruppen und polyoxyalkylengruppen sowie deren verwendung | |
BR0009622A (pt) | Sistema de borracha sem fim e veìculo contendo essa esteira | |
BR0000122A (pt) | Copolìmeros e uso dos mesmos com aditivos para melhorar as propriedades de escoamento a frio dos destilados intermediários | |
ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
BRPI0418123A (pt) | composição cosmética e utilização de um copolìmero | |
UA94231C2 (ru) | Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли | |
CY1117110T1 (el) | Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινων | |
FR2867679B1 (fr) | Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions. |